# Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg

> **NCT02952937** · PHASE1 · COMPLETED · sponsor: **GL Pharm Tech Corporation** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLA5PR GLARS-NF3 tablet 300mg
- **DRUG:** GLA5PR GLARS-NF1 tablet 300mg

## Key facts

- **NCT ID:** NCT02952937
- **Lead sponsor:** GL Pharm Tech Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2016-11
- **Final completion:** 2017-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02952937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02952937, "Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02952937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*